ASH 2023 | Poor outcomes of patients with AML who relapse underscores the need for effective initial treatment
Novel agents and combination regimens have substantially improved outcomes for patients with acute myeloid leukemia (AML); however, disease relapse remains a challenge and is associated with poor response rates, limited treatment options, and poor longer-term outcomes. Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, highlights data from a retrospective, single-center study that aimed to further understand the outcomes of patients with AML presenting at first relapse. This study confirmed that, although outcomes have improved, disease relapse remains a concern and that effective induction and maintenance regimens are needed to reduce the risk of relapse. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Prelude: Research Funding; Abbvie: Consultancy, Honoraria, Research Funding; Syros: Consultancy, Honoraria, Research Funding; Amgen: Honoraria, Research Funding; Astellas: Consultancy, Honoraria, Research Funding; Xencor: Research Funding; Biomea fusion: Honoraria, Research Funding; Celgene/BMS: Consultancy, Honoraria, Research Funding; Astex/taiho: Membership on an entity’s Board of Directors or advisory committees, Research Funding.
